Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182358 · ClinicalTrials.gov registry record · Phase 4
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
A Phase 4 study of Demodex Blepharitis, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 145
- Enrollment target
- 14
- Study locations
NCT06182358: Completed Phase 4 study of Demodex Blepharitis, sponsored by Tarsus Pharmaceuticals.
NCT06182358 is a Phase 4 study of Demodex Blepharitis that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 145 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). The trial reports 14 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182358, a Phase 4 study of Demodex Blepharitis, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 145 participants
- Enrollment target
- 14
- Study locations
Study Summary
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Primary Outcome
Change in collarette score at Day 43 compared to baseline, graded from 0 (0 to 2 lashes have collarettes per eyelid) to 4 ( 2/3 or more of lashes have collarettes per eyelid)
Conditions Studied
Interventions
- DRUG Lotilaner ophthalmic solution, 0.25%
- DRUG Vehicle control
Study Locations (14)
Arizona
- Site - Cave Creek
California
- Site - Long Beach
Colorado
- Vision Institute - Colorado Springs
Florida
- Site - Delray Beach
Indiana
- Site - Indianapolis
Kansas
- Site - Pittsburg
Kentucky
- Site - Louisville
Minnesota
- Site - Edina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 4 |
What the finished NCT06182358 record still lists
NCT06182358 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Demodex Blepharitis appearing as the primary indexed condition, and to 2 interventions - of which Lotilaner ophthalmic solution, 0.25% is the first listed.
NCT06182358 lists 14 locations in 14 states (Arizona, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06182358 about?
NCT06182358 is a clinical study titled "Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers". To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
What is the current status of trial NCT06182358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 145 participants. The study started on 2023-12-27. Estimated completion is 2025-01-27.
What conditions does trial NCT06182358 study?
This clinical trial studies the following conditions: Demodex Blepharitis.
What interventions are being tested in trial NCT06182358?
The interventions under investigation include: Lotilaner ophthalmic solution, 0.25% (DRUG), Vehicle control (DRUG).
Who is sponsoring clinical trial NCT06182358?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182358 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demodex Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06182358's enrollment target sits among peer trials
145 573rd of 2000 higher than 1,425 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI